Analysis of medication treatment for women with osteoporosis: A real-world retrospective study from Chinese tertiary grade A hospital

IF 2.1 Q3 ENDOCRINOLOGY & METABOLISM Bone Reports Pub Date : 2024-06-01 DOI:10.1016/j.bonr.2024.101778
Xiaolei Liu , Zhenling Zhu , Xianli Wang
{"title":"Analysis of medication treatment for women with osteoporosis: A real-world retrospective study from Chinese tertiary grade A hospital","authors":"Xiaolei Liu ,&nbsp;Zhenling Zhu ,&nbsp;Xianli Wang","doi":"10.1016/j.bonr.2024.101778","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>This study aimed to analyze the current medication treatment status for women with osteoporosis (OP) based on real-world prescription data from 2016 to 2021 in Chinese nine cities' tertiary Grade A hospital and systematically describe the medication treatment patterns in women with OP.</p></div><div><h3>Methods</h3><p>Prescription information for female OP patients in nine cities (Beijing, Shanghai, Guangzhou, Hangzhou, Tianjin, Zhengzhou, Chengdu, Shenyang, Harbin) was extracted from the Hospital Prescription Analysis Collaboration Project Database of the Hospital Pharmacy Professional Committee of the Chinese Pharmaceutical Association. Statistical analysis was conducted to evaluate demographic characteristics and medication treatment patterns.</p></div><div><h3>Results</h3><p>A total of 669,505 prescriptions for medication treatment of female OP patients were included in this study. The majority of patients were aged 60 to 99 years (69.79 %) followed by 50 to 59 years (18.81 %) and 40 to 49 years (6.69 %). Geographically, the highest concentration of patients was in North China (Beijing, Tianjin) (43.05 %) followed by East China (Shanghai, Hangzhou) (31.43 %). The top three prescribed medications were active vitamin D and its analogs (40.78 %), calcium supplements (32.51 %), and bisphosphonates (18.75 %). The prescription frequency of menopausal hormone therapy (MHT) was 0.31 %. The proportion of female OP patients receiving monotherapy and two drug combinations therapy is equivalent (about 37 %).</p></div><div><h3>Conclusion</h3><p>The diagnosis and treatment of female OP patients in China showed regional variations. The most commonly prescribed medications for this population were calcitriol, calcium carbonate with vitamin D3, and alendronate sodium with vitamin D3. The use of MHT was relatively limited.</p></div>","PeriodicalId":9043,"journal":{"name":"Bone Reports","volume":"21 ","pages":"Article 101778"},"PeriodicalIF":2.1000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2352187224000457/pdfft?md5=daf2c9d299476053c5e1df742a44ea63&pid=1-s2.0-S2352187224000457-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bone Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352187224000457","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose

This study aimed to analyze the current medication treatment status for women with osteoporosis (OP) based on real-world prescription data from 2016 to 2021 in Chinese nine cities' tertiary Grade A hospital and systematically describe the medication treatment patterns in women with OP.

Methods

Prescription information for female OP patients in nine cities (Beijing, Shanghai, Guangzhou, Hangzhou, Tianjin, Zhengzhou, Chengdu, Shenyang, Harbin) was extracted from the Hospital Prescription Analysis Collaboration Project Database of the Hospital Pharmacy Professional Committee of the Chinese Pharmaceutical Association. Statistical analysis was conducted to evaluate demographic characteristics and medication treatment patterns.

Results

A total of 669,505 prescriptions for medication treatment of female OP patients were included in this study. The majority of patients were aged 60 to 99 years (69.79 %) followed by 50 to 59 years (18.81 %) and 40 to 49 years (6.69 %). Geographically, the highest concentration of patients was in North China (Beijing, Tianjin) (43.05 %) followed by East China (Shanghai, Hangzhou) (31.43 %). The top three prescribed medications were active vitamin D and its analogs (40.78 %), calcium supplements (32.51 %), and bisphosphonates (18.75 %). The prescription frequency of menopausal hormone therapy (MHT) was 0.31 %. The proportion of female OP patients receiving monotherapy and two drug combinations therapy is equivalent (about 37 %).

Conclusion

The diagnosis and treatment of female OP patients in China showed regional variations. The most commonly prescribed medications for this population were calcitriol, calcium carbonate with vitamin D3, and alendronate sodium with vitamin D3. The use of MHT was relatively limited.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
女性骨质疏松症患者的药物治疗分析:一项来自中国三级甲等医院的真实世界回顾性研究
目的 本研究旨在基于中国九个城市三级甲等医院2016年至2021年的真实处方数据,分析女性骨质疏松症(OP)患者的药物治疗现状,并系统描述女性OP患者的药物治疗模式。方法从中国药学会医院药学专业委员会医院处方分析协作项目数据库中提取9个城市(北京、上海、广州、杭州、天津、郑州、成都、沈阳、哈尔滨)女性OP患者的处方信息。结果 本研究共纳入 669 505 份女性 OP 患者的药物治疗处方。大多数患者的年龄在 60 至 99 岁之间(69.79%),其次是 50 至 59 岁(18.81%)和 40 至 49 岁(6.69%)。从地域上看,患者最集中的地区是华北地区(北京、天津)(43.05%),其次是华东地区(上海、杭州)(31.43%)。处方药物的前三位是活性维生素 D 及其类似物(40.78%)、钙补充剂(32.51%)和双磷酸盐(18.75%)。更年期激素疗法(MHT)的处方频率为 0.31%。接受单一疗法和两种药物联合疗法的女性 OP 患者比例相当(约 37%)。该人群最常用的处方药是降钙素三醇、含维生素 D3 的碳酸钙和含维生素 D3 的阿仑膦酸钠。MHT的使用相对有限。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Bone Reports
Bone Reports Medicine-Orthopedics and Sports Medicine
CiteScore
4.30
自引率
4.00%
发文量
444
审稿时长
57 days
期刊介绍: Bone Reports is an interdisciplinary forum for the rapid publication of Original Research Articles and Case Reports across basic, translational and clinical aspects of bone and mineral metabolism. The journal publishes papers that are scientifically sound, with the peer review process focused principally on verifying sound methodologies, and correct data analysis and interpretation. We welcome studies either replicating or failing to replicate a previous study, and null findings. We fulfil a critical and current need to enhance research by publishing reproducibility studies and null findings.
期刊最新文献
Identifying the best reference gene for RT-qPCR analyses of the three-dimensional osteogenic differentiation of human induced pluripotent stem cells Naringin promotes osteogenic potential in bone marrow-derived mesenchymal stem cells via mediation of miR-26a/Ski axis Improvements with burosumab treatment in an early access programme for adults with X-linked hypophosphataemia: A case series of three patients Association of daily physical activity and bone microarchitecture in young adults with type 1 diabetes — A pilot exploratory study Zoledronate interrupts pre-osteoclast-induced angiogenesis via SDF-1/CXCR4 pathway
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1